Exploring Che-1/AATF's Role in Treating Multiple Myeloma
Inhibition of Che-1/AATF as a New Tool in Multiple Myeloma Treatment
This study is trying to understand how a protein called Che-1 affects the development of multiple myeloma to find new ways to treat this blood cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Sex | All |
| Sponsor | Regina Elena Cancer Institute Academic / other |
| Locations | 2 sites (Roma and 1 other locations) |
| Trial ID | NCT05858203 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the role of Che-1/AATF in the pathology of multiple myeloma, a complex blood cancer. By analyzing human samples, the study aims to characterize how Che-1 influences chromatin remodeling and global gene expression in multiple myeloma. The methodology includes advanced techniques such as ATAC-seq and ChIP-seq to study the involvement of Che-1 in tumorigenesis both in vivo and in vitro. The findings could provide insights into the molecular mechanisms underlying multiple myeloma and potential therapeutic targets.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with multiple myeloma.
Not a fit: Patients with other hematological malignancies or those not diagnosed with multiple myeloma may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new therapeutic strategies targeting Che-1/AATF in multiple myeloma treatment.
How similar studies have performed: While the specific approach of targeting Che-1/AATF in multiple myeloma is novel, similar studies have shown promise in understanding the molecular underpinnings of other cancers.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * MM Patients Exclusion Criteria: * No exclusion criteria
Where this trial is running
Roma and 1 other locations
- Regina elena Cancer Institute — Roma, Italy (Active_not_recruiting)
- "Regina Elena" National Cancer Institute — Rome, Italy (Recruiting)
Study contacts
- Study coordinator: Maurizio fanciulli, PhD
- Email: maurizio.fanciulli@ifo.it
- Phone: +39 06 52662800
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.